Clinical TrialsAll treated sickle cell disease patients are vaso-occlusive event free with follow-up from 2.4-22.8 months.
Financial PerformanceEDIT ended the quarter with $318.3 million in cash and equivalents, which are expected to fund operations into 2026.
Pipeline ProgressManagement highlighted positive data from EHA 2024 including sustained hemoglobin normalization, indicating reni-cel has the potential to be differentiated in the gene editing hemoglobinopathy space.